Venetoclax and obinutuzumab discontinuations due to AEs
| AEs . | Grade . | Study day of treatment discontinuation . |
|---|---|---|
| AEs leading to venetoclax discontinuation | ||
| R/R cohort | ||
| Diarrhea in context of ulcerative colitis* | 3 | 29 |
| Thrombocytopenia | 2 | 652 |
| Lymphopenia | 3 | |
| Autoimmune hemolytic anemia | 2 | 954 |
| Pneumonia in context of a metastatic squamous cell carcinoma of the lung† | 3 | 619 |
| Fatigue in context of persistent anemia | 2 | 331 |
| Intermittent long-lasting diarrhea | 1 | 575 |
| Esophageal adenocarcinoma | 3 | 722 |
| 1L cohort | ||
| Diarrhea | 3 | 346 |
| AEs leading to obinutuzumab discontinuation | ||
| R/R cohort | ||
| Lower respiratory tract infection | 2 | 29 |
| Ulcerative colitis* | 3 | 43 |
| 1L cohort–no discontinuations due to AEs |
| AEs . | Grade . | Study day of treatment discontinuation . |
|---|---|---|
| AEs leading to venetoclax discontinuation | ||
| R/R cohort | ||
| Diarrhea in context of ulcerative colitis* | 3 | 29 |
| Thrombocytopenia | 2 | 652 |
| Lymphopenia | 3 | |
| Autoimmune hemolytic anemia | 2 | 954 |
| Pneumonia in context of a metastatic squamous cell carcinoma of the lung† | 3 | 619 |
| Fatigue in context of persistent anemia | 2 | 331 |
| Intermittent long-lasting diarrhea | 1 | 575 |
| Esophageal adenocarcinoma | 3 | 722 |
| 1L cohort | ||
| Diarrhea | 3 | 346 |
| AEs leading to obinutuzumab discontinuation | ||
| R/R cohort | ||
| Lower respiratory tract infection | 2 | 29 |
| Ulcerative colitis* | 3 | 43 |
| 1L cohort–no discontinuations due to AEs |